Paulina Wieszczy

Paulina Wieszczy

Auto-generated profile, based on publicly available information

Paulina Wieszczy

Department of Gastroenterology, Hepatology and Oncology, Medical Center for Postgraduate Education, Warsaw, Poland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
MKMichel Kaminski
Michel Kaminski
PWPaulina Wieszczy
Paulina Wieszczy
MRMaciej Rupinski
Maciej Rupinski
UWUrszula Wojciechowska
Urszula Wojciechowska
JDJoanna Didkowska
Joanna Didkowska
JRJaroslaw Regula
Jaroslaw Regula

1 March 2020 in Gastroenterology
Verified
Journal Article
Open access
PWPaulina Wieszczy
Paulina Wieszczy
MKMichel Kaminski
Michel Kaminski
RFRobert Franczyk
Robert Franczyk
MLMagnus Loberg
Magnus Loberg
JKJarek Kobiela
Jarek Kobiela
JRJaroslaw Regula
Jaroslaw Regula
Recommendation of surveillance colonoscopy should be based on risk of colorectal cancer and death after adenoma removal. We aimed to develop a risk classification system based on colorectal cancer incidence and mortality following adenoma removal. We performed a multicenter population-based cohort study of 236,089 individuals (median patient age, 56 years; 37.8% male) undergoing screening colonoscopies with adequate bowel cleansing and cecum intubation at 132 centers in the Polish National Colorectal Cancer Screening Program, from 2000 through 2011. Subjects were followed for a median 7.1 years and information was collected on colorectal cancer development and death. We used recursive partitioning and multivariable Cox models to identify associations between colorectal cancer risk and patient and adenoma characteristics (diameter, growth pattern, grade of dysplasia, and number of adenomas). We developed a risk classification system based on standardized incidence ratios, using data from the Polish population for comparison. The primary endpoints were colorectal cancer incidence and colorectal cancer death. We identified 130 colorectal cancers in individuals who had adenomas removed at screening (46.5 per 100,000 person-years) vs 309 in individuals without adenomas (22.2 per 100,000 person-years). Compared with individuals without adenomas, adenomas ≥20 mm in diameter and high-grade dysplasia were associated with increased risk of colorectal cancer (adjusted hazard ratios 9.25; 95% confidence interval [CI] 6.39-13.39, and 3.58; 95% CI 1.96-6.54, respectively). Compared with the general population, colorectal cancer risk was higher or comparable only for individuals with adenomas ≥20 mm in diameter (standardized incidence ratio [SIR] 2.07; 95% CI 1.40-2.93) or with high-grade dysplasia (SIR 0.79; 95% CI 0.39-1.41), whereas for individuals with other adenoma characteristics the risk was lower (SIR 0.35; 95% CI 0.28-0.44). We developed a high-risk classification based on adenoma size ≥20 mm or high-grade dysplasia (instead of the current high-risk classification cutoff of ≥3 adenomas or any adenoma with villous growth pattern, high-grade dysplasia, or ≥10 mm in diameter). Our classification system would reduce the number of individuals classified as high-risk and requiring intensive surveillance from 15,242 (36.5%) to 3980 (9.5%), without increasing risk of colorectal cancer in patients with adenomas (risk difference per 100,000 person-years, 5.6; 95% CI -10.7 to 22.0). Using data from the Polish National Colorectal Cancer Screening Program, we developed a risk classification system that would reduce the number of individuals classified as high risk and require intensive surveillance more than 3-fold, without increasing risk of colorectal cancer in patients with adenomas. This system could optimize the use of surveillance colonoscopy.

28 September 2017 in Gut
Verified
Journal Article
Closed access
PDF file
MBMarek Bugajski
Marek Bugajski
PWPaulina Wieszczy
Paulina Wieszczy
GHGeir Hoff
Geir Hoff
MRMaciej Rupinski
Maciej Rupinski
JRJaroslaw Regula
Jaroslaw Regula
MKMichel Kaminski
Michel Kaminski
Objective Pain associated with colonoscopy is a major burden for patients. We investigated modifiable factors associated with patient-reported pain during and after colonoscopy. Design This cross-sectional analysis included database records from 23 centres participating in a population-based colonoscopy screening programme in Poland. Colonoscopies were performed under three sedation modalities: none, benzodiazepine-opioid sedation or propofol sedation. We used Gastronet (a validated tool) to assess patients’ pain during and after colonoscopy; pain was scored on a four-point scale (no, little, moderate or severe pain), with moderate to severe defined as painful. We used multivariate logistic regression models to estimate ORs for painful colonoscopy and calculated risk-adjusted ratios of painful colonoscopies per endoscopist and compared it to the mean rate. Results Of 35 216 screening colonoscopies in 2014 and 2015 included in our study, 22 725 (64.5%) patients returned valid Gastronet questionnaires. The proportion of examinations described as causing pain during (after) the procedure was 22.5% (14.2%) for unsedated, 19.9% (13.5%) for benzodiazepine-opioid sedation and 2.5% (7.5%) for propofol sedation. Propofol sedation, higher case volume of endoscopists, newest endoscope generation and adequate bowel preparation were significantly associated with lower odds of painful colonoscopy. Pain scores after colonoscopy showed similar associations. Adjusted pain rates during and after colonoscopy varied 11 and over 23-fold, respectively, between endoscopists. Conclusion We identified several independent, modifiable factors associated with pain during and after colonoscopy, of which individual endoscopist was the most important. Dedicated training should be considered to decrease variability among endoscopists.

12 March 2016 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PDF file
EZEdyta Zagórowicz
Edyta Zagórowicz
MBMarek Bugajski
Marek Bugajski
PWPaulina Wieszczy
Paulina Wieszczy
Anna Maria PietrzakAnna Maria Pietrzak
Anna Maria Pietrzak
AMAgnieszka Magdziak
Agnieszka Magdziak
AMAndrzej Mróz
Andrzej Mróz
Background and Aims Cytomegalovirus (CMV) often reactivates in the course of inflammatory bowel disease, but the significance of this remains disputable. Our aim was to evaluate whether severity of CMV colitis is associated with a colectomy risk in ulcerative colitis (UC) patients. The secondary aim was to evaluate agreement between immunohistochemistry (IHC) and blood CMV polymerase chain reaction (PCR). Methods UC patients with IHC CMV assessment in the colon hospitalized in a referral unit between 2005-2012 were retrospectively identified. The course and severity of the disease were analyzed, with inflammation graded histologically across the range 0-3. The numbers of IHC–positive cells per biopsy section were counted, while results for blood CMV PCR were also retrieved. Data on colectomies were also collected. Results Of 141 patients, 95 were analyzed, with 33 found to be IHC-positive, and 62 negative. The colectomy risk was significantly higher in patients with ≥5 IHC-positive cells, as opposed to those with none or less than 5 (p=0.014) with median follow-up of 1.9 and 3.2 years, respectively. The IHC-positive had lower hemoglobin (median 11.0 g/dl vs 12.0; p=0.028) and albumin (median 29.5 g/l vs 33.1; p=0.038) levels and more intense histologic inflammation (p=0.020) compared with the negative. There was substantial agreement between IHC and blood PCR (Cohen’s kappa coefficient 0.72). Conclusions Five or more CMV IHC-positive cells per biopsy section was indicative of a greater colectomy risk. CMV infection was related to more severe inflammation. Blood CMV PCR is a useful tool in UC.

1 September 2018 in Gastroenterology
Verified
Journal Article
Open access
PDF file
MKMette Kalager
Mette Kalager
PWPaulina Wieszczy
Paulina Wieszczy
ILIris Lansdorp-Vogelaar
Iris Lansdorp-Vogelaar
DCDouglas A. Corley
Douglas A. Corley
MBMichael Bretthauer
Michael Bretthauer
MKMichel Kaminski
Michel Kaminski
Overdiagnosis is recognized as a major harm of mammography screening for breast cancer and prostate cancer screening with prostate-specific antigen (PSA). Colorectal cancer (CRC) screening is being more broadly implemented in many countries, and screening rates are increasing steadily. Surprisingly, there is a striking and almost complete lack of knowledge about overdiagnosis in CRC screening. Overdiagnosis is not part of patient information material, hardly mentioned in guidelines, and not addressed in scientific or public debate. The present Commentary proposes a semantic, conceptual, and clinical framework for overdiagnosis in CRC screening.

1 June 2019 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
WJWladyslaw Januszewicz
Wladyslaw Januszewicz
PWPaulina Wieszczy
Paulina Wieszczy
ABAndrzej Bialek
Andrzej Bialek
KKKatarzyna Karpinska
Katarzyna Karpinska
JSJakub Szlak
Jakub Szlak
MKMichel Kaminski
Michel Kaminski